Sutro Biopharma (STRO) Cash & Equivalents (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Cash & Equivalents data on file, last reported at $58.1 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 69.45% year-over-year to $58.1 million; the trailing twelve-month figure through Dec 2025 stood at $58.1 million (down 69.45% YoY), and the FY2025 full-year result was $58.1 million, down 69.45% from the prior year.
• Cash & Equivalents slipped to $58.1 million in Q4 2025, from $65.9 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $235.1 million in Q2 2023 to a low of $28.9 million in Q1 2022.
• A 5-year average of $84.5 million and a median of $65.6 million in 2024 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 85.25% in 2021 and jumped 215.17% in 2022, its largest moves.
• Tracing STRO's Cash & Equivalents over 5 years: stood at $30.4 million in 2021, then soared by 55.37% to $47.3 million in 2022, then soared by 46.59% to $69.3 million in 2023, then jumped by 174.74% to $190.3 million in 2024, then tumbled by 69.45% to $58.1 million in 2025.
• Business Quant data shows STRO's Cash & Equivalents at $58.1 million in Q4 2025, $65.9 million in Q3 2025, and $64.0 million in Q2 2025.